P7 Medicine
P7 Medicine was founded by people who believe that everyone can make choices about health and life changes that face us during our lives.
Our aim is to educate, empower and enable individuals to understand personalized medicine, to share decisions about their medical care with their clinicians and to make informed choices about their own health and futures.
Our Vision
To develop the scientific and clinical basis necessary for realization of the concepts of Predictive and Personalized Medicine by using the modern diagnostic technologies and personalized therapy
Our Mission
Classification of diseases based on their molecular profiling rather than morphological and pathological characteristics to predict the response to treatment, and to enable the design of personalized therapies
P7 Units
p7 academy
Personalized medicine is based on the idea of using a patient’s genomic characteristics as a factor in deciding on the treatment options, but other factors are also taken into consideration as well.
Our philosophy
P1. Predictive Cellular Testing (Prediction of diseases development risk at very prima molecular stages before clinical symptoms)
P2. Preventive Healthcare Applying adequate diet and lifestyle to avoid probable diseases
P3. Precision Medicine (Precision diagnosis using the individuals’ biological data)
P4. point-of-care testing (Develop analysis methods used to facilitate sampling and sample transferring time)
P5. Personalized treatment (determination of the best individual treatment method for each person based on cases molecular genetic properties)
P6. Personalized monitoring (Gathering all the experts and physicians together close to patient to manage the whole process from the first diagnostic step to the end)
P7. Patient management (Gathering all the expert and physicians together close to patient to manage the whole process from the first diagnostic step to the end
How We Work
News
European Approval Makes Atara’s Ebvallo™ First Allogeneic T-Cell Therapy Approved Worldwide
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+
International Congress Registration
International congress on the application of new technologies of stem cells and genetics in Personalized Medicine In the
crispr cas9 gene editing used cut out mutation early study
System shows proof-of-concept effects in reducing production of toxic molecules A CRISPR/Cas9 gene editing system can be used
